Vaxcell-Bio Therapeutics Co., Ltd. is a South Korean biotechnology company specializing in the research, development, manufacturing, and commercialization of cancer immunotherapy products. Its core products include cell-based immunotherapies such as the Vax-NK natural killer cell platform; the Vax-DC dendritic cell platform; and next-generation CAR therapies including the Vax-CAR series, which target solid tumors and hematological cancers. The company also produces cytokine-based immunotherapy products like Bosuleukin-15 specifically for canine cancer treatment. Founded in 2010 and headquartered in Hwasun-eup, South Korea, Vaxcell-Bio operates primarily within South Korea while also targeting overseas markets. Recent major developments include the completion of the acquisition of ALBIOTEK Co., Ltd. in early 2025, strategic alliances for advancing CAR-NK and CAR-T cell therapies aimed at solid tumors, and significant progress in clinical trials for its Vax-NK therapies showing superior efficacy in liver and pancreatic cancers. The company has also secured patents for novel dual-target CAR-T therapies and received government grants to develop next-generation CAR-NK and CAR-MIL cell therapies. Additionally, Vaxcell-Bio is expanding its capabilities in cell therapy contract development and manufacturing organizations (CDMO) and partnering with institutions such as Seoul National University for innovative treatments including macular degeneration. These actions emphasize Vaxcell-Bio’s focus on advancing cellular immuno-oncology and expanding its product offerings in cancer immunotherapy markets.